Novartis will pay $72 a share in cash for the biotechnology company, representing a premium of 46% to Avidity’s closing price ...

(Oct 27): Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc in a deal valued at US$12 billion, making ...

Sen. Bill Cassidy, MD (R-La.), chair of the committee, applauded medical innovations of the last few decades including ...

Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug. | ...

NEW YORK] Novartis agreed to buy biotechnology company Avidity Biosciences in a deal that values it at US$12 billion, ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

The biotechnology giant’s board will front angry investors this week after losing more than a quarter of its market value ...

Alexandria Real Estate Equities, Inc. faces ongoing headwinds, with soft biotech demand, and declining occupancy. Learn more ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

Cytokinetics (CYTK) shares have moved in line with broader biotech trends, as investors pay close attention to recent performance data. Over the past month, the stock has climbed 15%, reflecting ...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) shares have shown interesting movement recently, supported by a mix of strong revenue growth and improved net income figures. Investors are watching ...

Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...